Floatz logo

Hyperacute-Lung Cancer Vaccine

Lung Neoplasms

NewLink Genetics CorporationvaccinePhase 1/2Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
73/ 100

Competitive context

52 Active assets in the Lung Neoplasms cohort.

Asset / SponsorPhaseRating
Carboplatin
Nanfang Hospital, Southern Medical University
Phase 4BB
Nivolumab
Hospital Israelita Albert Einstein
Phase 2BB
BELAGENPUMATUCEL-L (SK-LU-1)
NovaRx Corporation
Phase 3BB
Icotinib
Fuda Cancer Hospital, Guangzhou
Phase 4BB
Rivoceranib
Fuzhou General Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

Hyperacute-Lung Cancer Vaccine is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
lung adenocarcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
lung large cell carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →